Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 6:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 394 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Malignant Glioma, Recurrent Brain Neoplasm, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Glioblastoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm, WHO Grade 3 Glioma
Interventions
Pharmacological Study, Selinexor
Other · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 21 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more
Conditions
Childhood Cerebellar Anaplastic Astrocytoma, Childhood Cerebral Anaplastic Astrocytoma, Childhood Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Subependymal Giant Cell Astrocytoma
Interventions
Diagnostic Laboratory Biomarker Analysis, Pharmacological Study, Sunitinib Malate
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
86
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 71 more
Conditions
Brain and Central Nervous System Tumors
Interventions
cintredekin besudotox, adjuvant therapy, conventional surgery, neoadjuvant therapy
Biological · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
New York, New York
Conditions
Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme, Brain Neoplasms, Malignant, Leptomeningeal Disease (LMD)
Interventions
Radiation Therapy, AZD1390
Radiation · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania + 1 more
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ABT-751
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Up to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
3
States / cities
Chicago, Illinois • Bethesda, Maryland • Philadelphia, Pennsylvania
Conditions
Brain and Central Nervous System Tumors
Interventions
aldesleukin, autologous tumor cell vaccine, muromonab-CD3, sargramostim, therapeutic autologous lymphocytes, surgical procedure, radiation therapy
Biological · Procedure · Radiation
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Brain and Central Nervous System Tumors
Interventions
imatinib mesylate, temozolomide, pharmacological study
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Malignant Glioma, Glioma, Glioblastoma, Glioblastoma Multiforme, Astrocytoma
Interventions
Aminolevulinic Acid
Drug
Lead sponsor
MultiCare Health System Research Institute
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Tacoma, Washington
Conditions
Brain Tumor, Recurrent
Interventions
Photofrin photodynamic therapy.
Drug
Lead sponsor
Harry T Whelan, MD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Glioblastoma, Malignant Glioma, Recurrent Glioma, Refractory Glioma, WHO Grade III Glioma
Interventions
HER2(EQ)BBζ/CD19t+ T cells, Laboratory Biomarker Analysis, Leukapheresis
Biological · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Duarte, California
Conditions
Acoustic Schwannoma, Adult Anaplastic (Malignant) Meningioma, Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Brain Stem Glioma, Adult Choroid Plexus Neoplasm, Adult Craniopharyngioma, Adult Diffuse Astrocytoma, Adult Ependymoblastoma, Adult Ependymoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Grade I Meningioma, Adult Grade II Meningioma, Adult Medulloblastoma, Adult Mixed Glioma, Adult Myxopapillary Ependymoma, Adult Oligodendroglioma, Adult Papillary Meningioma, Adult Pilocytic Astrocytoma, Adult Pineal Gland Astrocytoma, Adult Pineoblastoma, Adult Pineocytoma, Adult Primary Melanocytic Lesion of Meninges, Adult Subependymal Giant Cell Astrocytoma, Adult Subependymoma, Adult Supratentorial Primitive Neuroectodermal Tumor, Malignant Adult Intracranial Hemangiopericytoma
Interventions
3-Dimensional Conformal Radiation Therapy, Gamma-Secretase Inhibitor RO4929097, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Pharmacological Study, Temozolomide, Therapeutic Conventional Surgery
Radiation · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
2
States / cities
New York, New York • Charlottesville, Virginia
Conditions
Glioblastoma, Gliosarcoma
Interventions
EGFRvIII CAR T cells
Biological
Lead sponsor
Daniel Landi
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Glioma, Glioblastoma, Glioblastoma Multiforme, GBM, Brain Cancer
Interventions
VAL-083 (Dianhydrogalactitol)
Drug
Lead sponsor
Kintara Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
5
States / cities
San Francisco, California • Denver, Colorado • Sarasota, Florida + 2 more
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Chordoma, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma
Interventions
amifostine trihydrate, busulfan, filgrastim, melphalan, thiotepa, peripheral blood stem cell transplantation (PBSC)
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
1 Year to 45 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme of Brain, Astrocytoma, Malignant, Brain Neoplasms, Brain Neoplasms, Adult, Malignant, Brain Neoplasms, Adult, Recurrent Adult Brain Tumor, Recurrent Glioblastoma
Interventions
Awake mapping under local anesthesia, Asleep mapping under general anesthesia, Resection under general anesthesia without mapping
Procedure
Lead sponsor
Erasmus Medical Center
Other
Eligibility
Up to 90 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
San Francisco, California • Boston, Massachusetts
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
gamma-secretase/Notch signalling pathway inhibitor RO4929097, bevacizumab, laboratory biomarker analysis, pharmacological study
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Tampa, Florida + 1 more
Conditions
Brain and Central Nervous System Tumors
Interventions
thalidomide, topotecan hydrochloride
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Glioblastoma, Lung Carcinoma, Malignant Solid Neoplasm, Metastatic Breast Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Duarte, California
Conditions
Brain and Central Nervous System Tumors
Interventions
O6-benzylguanine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2009
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 6 more
Conditions
Brain and Central Nervous System Tumors
Interventions
filgrastim, sargramostim, cyclophosphamide, thiotepa, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2008
U.S. locations
2
States / cities
Paterson, New Jersey • New York, New York
Conditions
Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Ganglioglioma, Anaplastic Meningioma, Anaplastic Oligodendroglioma, Pleomorphic Xanthoastrocytoma, Anaplastic, Atypical Teratoid/Rhabdoid Tumor, Brain Cancer, Brain Tumor, Central Nervous System Neoplasms, Choroid Plexus Carcinoma, CNS Embryonal Tumor With Rhabdoid Features, Ganglioneuroblastoma of Central Nervous System, CNS Tumor, Embryonal Tumor of CNS, Ependymoma, Glioblastoma, Glioma, Glioma, Malignant, Medulloblastoma, Medulloblastoma; Unspecified Site, Medulloepithelioma, Neuroepithelial Tumor, Neoplasms, Neoplasms, Neuroepithelial, Papillary Tumor of the Pineal Region (High-grade Only), Pediatric Brain Tumor, Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only), Pineoblastoma, Primitive Neuroectodermal Tumor, Recurrent Medulloblastoma, Refractory Brain Tumor, Neuroblastoma. CNS, Glioblastoma, IDH-mutant, Glioblastoma, IDH-wildtype, Medulloblastoma, Group 3, Medulloblastoma, Group 4, Glioma, High Grade, Neuroepithelial Tumor, High Grade, Medulloblastoma, SHH-activated and TP53 Mutant, Medulloblastoma, SHH-activated and TP53 Wildtype, Medulloblastoma, Chromosome 9q Loss, Medulloblastoma, Non-WNT Non-SHH, NOS, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, PTCH1 Mutation, Medulloblastoma, WNT-activated, Ependymoma, Recurrent, Glioma, Recurrent High Grade, Glioma, Recurrent Malignant, Embryonal Tumor, NOS, Glioma, Diffuse Midline, H3K27M-mutant, Embryonal Tumor With Multilayered Rosettes (ETMR), Ependymoma, NOS, WHO Grade III, Ependymoma, NOS, WHO Grade II, Medulloblastoma, G3/G4, Ependymoma, RELA Fusion Positive
Interventions
Gemcitabine, ribociclib, sonidegib, trametinib, filgrastim
Drug · Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 39 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Brain and Central Nervous System Tumors
Interventions
bevacizumab
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Chicago, Illinois
Conditions
Brain and Central Nervous System Tumors
Interventions
Erlotinib + Sirolimus
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Mind-Body Intervention in Glioma Couples

NCT03244995
Conditions
Glioblastoma, Low Grade Glioma, Malignant Glioma, Metastatic Malignant Neoplasm in the Brain, Partner, WHO Grade III Glioma
Interventions
Mind-Body Intervention Procedure, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2028
U.S. locations
1
States / cities
Houston, Texas